Systemic Delivery of Targeted Bi-Compartmental Nanoparticles for Glioblastoma Therapeutics

用于胶质母细胞瘤治疗的靶向双室纳米颗粒的系统递送

基本信息

  • 批准号:
    10584553
  • 负责人:
  • 金额:
    $ 48.16万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-03-15 至 2027-02-28
  • 项目状态:
    未结题

项目摘要

Abstract Glioblastoma multiforme (GBM) is the prevalent primary malignant brain tumor accounting for 80% of all brain cancer patients. It is typically associated with poor prognosis. The standard of care for GBM patients consists of bulk surgical resection of the tumor mass in combination with focal radiotherapy and adjuvant chemotherapy, using temozolomide (TMZ). Despite intense efforts, the prognosis of glioma patients remains dismal. Novel approaches are greatly needed for this devastating form of brain cancer. Signal and Transducer of Activation 3 (STAT3) transcription factor has been proven to be a very attractive therapeutic target for malignant brain tumors, as their growth is highly dependent of STAT3 signaling. Preliminary data from our team clearly suggest that currently available small molecule STAT3 inhibitors are highly effective at eliciting regression of GBM tumors growing in the periphery. In contrast, these same small molecule STAT3 inhibitors were ineffective in treating GBM tumors located within the brain. We demonstrated that the lack of efficacy is due to limited BBB transport. Similar difficulties are encountered for the delivery of other established chemotherapeutics, specifically paclitaxel (PTX). Nanoparticle-based drug delivery systems offer potential solutions, but current delivery carriers have still relatively low efficacy or require invasive intracranial delivery, to enable transport of therapeutics across the blood-brain-barrier. In our preliminary studies, we were able to demonstrate that albumin-based drug delivery carriers developed by our group significantly accumulate in intracranial tumors after systemic administration. In this proposal, our interdisciplinary team will develop and evaluate a novel and scalable bi-compartmental human serum albumin-based carrier system that allows controlled encapsulation of therapeutic ratios of STAT3 siRNA and PTX within distinct compartments of the same albumin-based drug delivery carrier, while also incorporating tumor-penetrating peptides, which have been previously shown to promote nanoparticle penetration into GBMs. The experiments will test the hypothesis that the proposed bi-compartmental (bi-NP) STAT3i/PTX delivery carriers in combination with standard of care, i.e., radiation therapy (IR) and TMZ, will significantly improve medial survival of intracranial GBM bearing mice. We also hypothesize that the co-release of STAT3 siRNA and PTX, when spatially and temporally orchestrated by an appropriately designed delivery carrier, will not exhibit untoward adverse side effects in the host, neither within the brain, nor systemically. This work may result in a new treatment modality for GBM, a tumor type, for which no effective treatments exist. New information on accessing brain tumors with drugs will also ensue. Our ultimate goal is to translate this novel therapeutic modality to patients with GBM by implementing Phase I clinical trials.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Maria G Castro其他文献

Maria G Castro的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Maria G Castro', 18)}}的其他基金

Uncover the role of H3.3-G343R mutation in shaping the DNA damage response, anti-tumor immunity and mechanisms of resistance in glioma.
揭示 H3.3-G343R 突变在塑造神经胶质瘤 DNA 损伤反应、抗肿瘤免疫和耐药机制中的作用。
  • 批准号:
    10384185
  • 财政年份:
    2022
  • 资助金额:
    $ 48.16万
  • 项目类别:
Uncover the role of H3.3-G343R mutation in shaping the DNA damage response, anti-tumor immunity and mechanisms of resistance in glioma.
揭示 H3.3-G343R 突变在塑造神经胶质瘤 DNA 损伤反应、抗肿瘤免疫和耐药机制中的作用。
  • 批准号:
    10550245
  • 财政年份:
    2022
  • 资助金额:
    $ 48.16万
  • 项目类别:
Systemic Delivery of Targeted Bi-Compartmental Nanoparticles for Glioblastoma Therapeutics
用于胶质母细胞瘤治疗的靶向双室纳米颗粒的系统递送
  • 批准号:
    10462033
  • 财政年份:
    2022
  • 资助金额:
    $ 48.16万
  • 项目类别:
Novel nano-vaccine technology for inducing immunity against gliomas
用于诱导神经胶质瘤免疫力的新型纳米疫苗技术
  • 批准号:
    10655464
  • 财政年份:
    2021
  • 资助金额:
    $ 48.16万
  • 项目类别:
Administrative Diversity Supplement- Novel Nano-Vaccine Technology for Inducing Immunity Against Gliomas
行政多样性补充-诱导神经胶质瘤免疫的新型纳米疫苗技术
  • 批准号:
    10622660
  • 财政年份:
    2021
  • 资助金额:
    $ 48.16万
  • 项目类别:
Novel nano-vaccine technology for inducing immunity against gliomas
用于诱导神经胶质瘤免疫力的新型纳米疫苗技术
  • 批准号:
    10443896
  • 财政年份:
    2021
  • 资助金额:
    $ 48.16万
  • 项目类别:
Chemo-immunotherapy strategy for pediatric high grade glioma
儿童高级别胶质瘤的化学免疫治疗策略
  • 批准号:
    10296214
  • 财政年份:
    2021
  • 资助金额:
    $ 48.16万
  • 项目类别:
Novel nano-vaccine technology for inducing immunity against gliomas
用于诱导神经胶质瘤免疫力的新型纳米疫苗技术
  • 批准号:
    10877283
  • 财政年份:
    2021
  • 资助金额:
    $ 48.16万
  • 项目类别:
Novel nano-vaccine technology for inducing immunity against gliomas
用于诱导神经胶质瘤免疫力的新型纳米疫苗技术
  • 批准号:
    10241830
  • 财政年份:
    2021
  • 资助金额:
    $ 48.16万
  • 项目类别:
Immune-suppressive Myeloid Cells in the Glioma Microenvironment: Signaling Mechanisms and Novel Therapeutic Strategies
胶质瘤微环境中的免疫抑制骨髓细胞:信号传导机制和新的治疗策略
  • 批准号:
    9981837
  • 财政年份:
    2015
  • 资助金额:
    $ 48.16万
  • 项目类别:

相似海外基金

3D Engineered Model of Microscopic Colorectal Cancer Liver Metastasis for Adjuvant Chemotherapy Screens
用于辅助化疗筛选的显微结直肠癌肝转移 3D 工程模型
  • 批准号:
    10556192
  • 财政年份:
    2023
  • 资助金额:
    $ 48.16万
  • 项目类别:
Developing Digital Pathology Biomarkers for Response to Neoadjuvant and Adjuvant Chemotherapy in Breast Cancer
开发数字病理学生物标志物以应对乳腺癌新辅助和辅助化疗
  • 批准号:
    10315227
  • 财政年份:
    2021
  • 资助金额:
    $ 48.16万
  • 项目类别:
Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colorectal Cancer: A Multicentre Phase II/III Randomised Controlled Trial (DYNAMIC-III)
循环肿瘤 DNA 分析为 III 期结直肠癌辅助化疗提供信息:多中心 II/III 期随机对照试验 (DYNAMIC-III)
  • 批准号:
    443988
  • 财政年份:
    2021
  • 资助金额:
    $ 48.16万
  • 项目类别:
    Operating Grants
Establishment of new selection system for adjuvant chemotherapy of colorectal cancer
结直肠癌辅助化疗新选择体系的建立
  • 批准号:
    20K09011
  • 财政年份:
    2020
  • 资助金额:
    $ 48.16万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improved survival by Helicobacter pylori-modulated immunity in gastric cancer patients with adjuvant chemotherapy
幽门螺杆菌调节免疫力可改善接受辅助化疗的胃癌患者的生存率
  • 批准号:
    19K09130
  • 财政年份:
    2019
  • 资助金额:
    $ 48.16万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A new strategy of adjuvant chemotherapy for lung cancer based on the expression of anti-aging gene Klotho
基于抗衰老基因Klotho表达的肺癌辅助化疗新策略
  • 批准号:
    19K18225
  • 财政年份:
    2019
  • 资助金额:
    $ 48.16万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer
预测胰腺癌S-1辅助化疗效果的新候选因素
  • 批准号:
    18K16337
  • 财政年份:
    2018
  • 资助金额:
    $ 48.16万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Project 2-Metabolic Modulation of Myeloid-Derived Suppressor Cells to Increase Efficacy of Neo adjuvant Chemotherapy and Immunotherapy
项目2-骨髓源性抑制细胞的代谢调节以提高新辅助化疗和免疫疗法的疗效
  • 批准号:
    10005254
  • 财政年份:
    2018
  • 资助金额:
    $ 48.16万
  • 项目类别:
Radiogenomic tools for prediction of breast cancer neo-adjuvant chemotherapy response from pre-treatment MRI
通过治疗前 MRI 预测乳腺癌新辅助化疗反应的放射基因组学工具
  • 批准号:
    9763320
  • 财政年份:
    2018
  • 资助金额:
    $ 48.16万
  • 项目类别:
Analysis of the molecular mechanism for the prognostic biomarker of adjuvant chemotherapy
辅助化疗预后生物标志物的分子机制分析
  • 批准号:
    18K07341
  • 财政年份:
    2018
  • 资助金额:
    $ 48.16万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了